Welcome to Dr. Irtisha Singh’s Laboratory

Understanding Gene Regulation in Cancer Biology and Regenerative Medicine

Welcome to the Singh Lab! We are located in the Department of Molecular and Cellular Medicine, College of Medicine, Texas A&M Health Science Center. The primary goal of our laboratory is to model and understand the molecular basis of tumor development, progression, and response to therapy. Our laboratory applies and develop computational, molecular, and chemical biology approaches to understand mechanisms of transcriptional deregulation in cancer and the consequences of targeting the chromatin and transcription apparatus on cancer cell state. A parallel focus of our laboratory is to develop and use cellular engineered models of cancer cell state to discern the role of tumor microenvironment supporting neoplastic transformation. This integrated approach brings together a range of seemingly disparate disciplines that will address some of the complexity associated with cancer bioengineering and regenerative medicine in a manner that is otherwise not possible. The immediate focus of our laboratory is:

  1. Cancer epigenetics: Understand chromatin-directed oncogenic transformation in glioblastoma. Specifically, we aim to systematically characterize the oncogenic role of candidate transcription factors (TFs) as drivers of tumorigenesis in glioblastoma and identify their downstream target oncogenes with a potential therapeutic window.
  2. Bioengineered tumor organoids: Develop and validate bioengineered glioblastoma 3D organoids from glioblastoma stem cells (GSCs). We aim to utilize these bioengineered glioblastoma 3D organoids to understand the molecular regulation of GSCs in a microenvironment mimicking its native surroundings.
  3. Cancer RNA biology: Compile a comprehensive atlas of intronic polyadenylation (IPA) isoforms across 38 cancer types present in The Cancer Genome Atlas (TCGA), followed by determination of IPA sites that are regulated differently in tumors compared to their normal. Furthermore, we will assess the functional consequences of IPA dysregulation in different cancer types.
  4. Regenerative medicine: Utilize genome wide sequencing assays (transcriptomics and chromatin accessibility) to understand complex cell-biomaterials interactions. Specifically, we will utilize these omics-based approaches to provide an unbiased global view of the cellular activity with pivotal insights about the affected cellular pathways to optimize synthetic biomaterials for tissue engineering.